News
April 5th 2024
BOYDSense raises €7m in a capital increase to further develop its non-invasive glucose monitoring device.
BOYDSense, a medical device company developing a platform that makes health monitoring simple and pain free, powered by breath, announces the completion of a 7-million-euro capital increase.
Press Release
July 17th 2023
The French media “La Tribune” puts BOYDSense in the spotlight
The Toulouse-based company frees diabetics from finger pricks: BOYDSense, an Alpha MOS company, is finalizing the development of an electronic breath glucose meter that could well change the lives of people with diabetes.
News
June 1st 2023
Conclusion of the 2nd BOYDSense clinical study
Alpha MOS, world leader in smell, taste and visual industrial instrument analyzers, announces the on-schedule completion of the 2nd clinical study on the non-invasive breath glucose monitoring device developed by its Medtech subsidiary, BOYDSense.
News
February 7th 2023
BOYDSense selected among the 12 most innovative French Medtech by the National Union of the Medical Technology Industry.
BOYDSense SAS, subsidiary of Alpha MOS, has been selected by a jury from the National Union of the Medical Technology Industry (SNITEM) in order to participate to the 8th edition of the start-ups day, organized on April 4th at la Cité des Sciences.
Press Release
February 3rd 2022
Ben Delhey appointed as CEO of BOYDSense, the MedTech subsidiary of Alpha MOS
We are developing a miniaturized breath analysis platform to monitor chronic diseases, with a first application in diabetes. Today we are announcing the appointment of Ben Delhey as CEO of the company.
If you would like to start a conversation with us, please get in touch:
By submitting your data, you are consenting to receive marketing or communications from us. To understand how we use your data, please read our Privacy Notice.
At BOYDSense we believe in the potential of breath analysis to revolutionise health monitoring and management.
Sign up to hear more about our ongoing device, technology and platform development including our latest clinical trials and investment rounds.
By submitting your data, you are consenting to receive marketing or communications from us. To understand how we use your data, please read our Privacy Notice.
We use cookies to analyze site usage. By clicking "Accept", you consent to our use of cookies. You can choose to accept or reject cookies, or adjust your preferences below.